降纤酶治疗不稳定型心绞痛的临床观察

Clinical Evaluation of Defibrinogenase in Treatment of Unstable Angina Pectoris

目的 :探讨降纤酶 (Dfb)治疗不稳定型心绞痛 (UAP)的疗效。方法 :将 6 2例UAP患者随机分组 :A组 (32例 )给予口服阿斯匹林 (30 0mg·d-1)和抗心绞痛药 ,B组 (30例 )在A组治疗基础上 ,另加Dfb(10U·d-1共 3d)静脉点滴。结果 :A组和B组在住院 10d内每天心绞痛发作次数、非致死性心肌梗死、心性死亡、2 4h缺血总负荷、 ST及纤维蛋白原分别为 :5 .5± 2 .3与 3 .2± 0 .5 (P <0 .0 1)、9%与 0 (P <0 .0 1)、6 %与 0 (P <0 .0 1) ,186 8± 846与735± 2 82 (P <0 .5 )、3.4± 0 .7与 1.4± 0 .6 (P <0 .0 1)、3 .9± 0 .6与 1.0± 0 .4(P <0 .0 1) ,B组无一例发生出血倾向。结论 :UAP患者急性期用Dfb治疗有效。

Objective: To study the efficacy of defibrinogenase(Dfb) in treatment of unstable angina pectoris(UAP).Methods: 62 patients with UAP were randomly divided into two groups:32 cases of group A were treated with Aspirin (300 mg·d -1 a(c)&lt;1and Anti anginal durgs, while the other 30 cases of group B were with Bfb of 10 u i.v.gtt.qd×3d.Results:The rates of angina pectoris,non death myocardial infraction,death from cardio attack,24 hours total and myocardial ischemic, ∑ST as well as firbrinogen levels in group A were significantly higher than those in group B ( P &lt;0.01) 9%vs0( P ,0.01)6%vs0( P &lt;0.01)1868±846vs735±282( P &lt;0.05)3.4±0.7vs1.4±0.6( P &lt;0.01)3.9±0.6vs1.0±0.4( P &lt;0.01).None of group B was found to have hemorrhage.Conclusion:Dfb is a safe,effective, and reliable drug to treat the UAP at acute stage.